ChromaDex (NASDAQ:CDXC) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of ChromaDex (NASDAQ:CDXC) in a research report issued on Thursday. The brokerage set a “buy” rating on the stock.

Several other research firms have also commented on CDXC. LADENBURG THALM/SH SH raised their price objective on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of ChromaDex in a research report on Monday, March 17th.

ChromaDex Stock Performance

The firm has a market cap of $611.50 million, a P/E ratio of 787.29 and a beta of 2.21. The business’s 50 day moving average price is $6.16 and its two-hundred day moving average price is $5.44. ChromaDex has a twelve month low of $2.31 and a twelve month high of $9.18.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. D. E. Shaw & Co. Inc. boosted its stake in ChromaDex by 1,785.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock valued at $5,365,000 after purchasing an additional 957,665 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of ChromaDex by 288.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock worth $3,517,000 after buying an additional 492,148 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of ChromaDex by 189.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 506,186 shares of the company’s stock valued at $2,685,000 after purchasing an additional 331,014 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of ChromaDex during the 4th quarter valued at $1,647,000. Finally, Renaissance Technologies LLC grew its stake in ChromaDex by 68.0% in the fourth quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock valued at $3,781,000 after purchasing an additional 288,588 shares in the last quarter. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.